Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beclomethasone (also known as beclometasone or beclomethasone dipropionate) is a synthetic glucocorticoid corticosteroid used primarily for its anti-inflammatory and immunosuppressive properties. It is available in several formulations including inhalers (for asthma), nasal sprays (for allergic rhinitis and nasal polyps), creams (for dermatitis and psoriasis), and oral pills (occasionally for ulcerative colitis)[8][3]. The inhaled form is widely used in the long-term management of asthma by reducing airway inflammation and hyper-reactivity[1][2][3]. Its mechanism of action involves binding to the glucocorticoid receptor to inhibit pro-inflammatory signals while promoting anti-inflammatory gene expression[3]. Beclomethasone was first patented in 1962 and approved for medical use in 1976[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclomethasone.